Revance Therapeutics Inc. (NASDAQ:RVNC) shares traded up 5.9% during mid-day trading on Thursday . The stock traded as high as $14.66 and last traded at $14.61, with a volume of 71,008 shares changing hands. The stock had previously closed at $13.79.

Several research analysts have recently issued reports on the stock. Piper Jaffray Cos. restated an “overweight” rating and issued a $35.00 target price (down previously from $54.00) on shares of Revance Therapeutics in a report on Tuesday, June 14th. SunTrust Banks Inc. lowered their target price on shares of Revance Therapeutics from $46.00 to $22.00 and set a “buy” rating for the company in a report on Tuesday, June 14th. Zacks Investment Research upgraded shares of Revance Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 target price for the company in a report on Wednesday, July 13th. Guggenheim restated a “buy” rating and issued a $55.00 target price on shares of Revance Therapeutics in a report on Tuesday, June 14th. Finally, Brean Capital restated a “hold” rating on shares of Revance Therapeutics in a report on Friday, August 5th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $39.60.

The firm has a 50 day moving average price of $13.62 and a 200 day moving average price of $17.04. The firm’s market capitalization is $420.14 million.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by $0.02. The business had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $0.06 million. The business’s revenue was up .0% compared to the same quarter last year. On average, equities analysts forecast that Revance Therapeutics Inc. will post ($3.53) earnings per share for the current year.

Revance Therapeutics, Inc is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.